Skip to Content
Global News Select

Teva Pharma Shares Up 10% on Release of EpiPen Jr in U.S.

By Chris Wack


Shares of Teva Pharmaceutical Industries (TEVA) rose 10% to $7.35 after the company announced availability of an FDA-approved generic version of EpiPen Jr Auto-Injector, 0.15 mg, in the U.S.

The company said the product is available in most retail pharmacies at $300 for a 2-pack.

Teva's generic equivalent of EpiPen Jr uses Antares Pharma's (ATRS) VIBEX device. Antares and Teva have an exclusive license, development and supply agreement for epinephrine auto injector products that Teva markets in the U.S.


Write to Chris Wack at


(END) Dow Jones Newswires

August 20, 2019 10:13 ET (14:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.